Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Open Access
- 12 July 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 120 (2), 376-385
- https://doi.org/10.1182/blood-2012-02-412783
Abstract
The attrition rate for anticancer drugs entering clinical trials is unacceptably high. For multiple myeloma (MM), we postulate that this is because oKeywords
This publication has 40 references indexed in Scilit:
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaCancer, 2010
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myelomaBlood, 2010
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaHaematologica, 2009
- Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I studyBritish Journal of Cancer, 2009
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- A low-viscosity epoxy resin embedding medium for electron microscopyJournal of Ultrastructure Research, 1969